Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2020; 26(30): 4537-4556
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4537
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4537
Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review
Mohid S Khan, Department of Gastroenterology and Neuroendocrine Tumours, University Hospital of Wales, Cardiff CF14 4XW, United Kingdom
Thomas Walter, Department d'Oncologie Médicale, Hospices Civils de Lyon, Lyon 69003, France
Amy Buchanan-Hughes, Emma Worthington, Evidence Development, Costello Medical, Cambridge CB1 2JH, United Kingdom
Lucie Keeber, Medical Affairs, Ipsen, Slough SL1 3XE, United Kingdom
Marion Feuilly, Health Economics and Outcomes Research, Ipsen, Boulogne-Billancourt 92100, France
Enrique Grande, Oncology Department, MD Anderson Cancer Center, Madrid 28033, Spain
Author contributions: Khan MS, Walker T, Buchanan-Hughes A, Worthington E, Keeber L, Feuilly M and Grande E each made substantial contributions to study conception and design, analysis and interpretation of the data, drafting the article or revising it critically for important intellectual content, and final approval of the version of the article to be published.
Supported by Ipsen.
Conflict-of-interest statement: MK has received sponsorship for meeting attendance, and honoraria for advisory boards from Novartis, Ipsen, Pfizer and BMS. TW has received honoraria for advisory boards and lectures from Keocyt, Ipsen, Novartis, and Adacap. TW has received research grants from Roche, Ipsen and Novartis. EG has received honoraria for advisory boards, meetings and/or lectures from Pfizer, BMS, Ipsen, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon and Celgene. EG has received unrestricted research grants from Pfizer, Astra Zeneca, MTEM/Threshold, Roche, Ipsen and Lexicon. ABH and EW are employees of Costello Medical. LK and MF are employees of Ipsen.
PRISMA 2009 Checklist statement: This is study followed PRISMA guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Mohid S Khan, BSc, FRCP, MBBS, PhD, Doctor, Department of Gastroenterology and Neuroendocrine Tumours, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, United Kingdom. khanms14@cardiff.ac.uk
Received: March 5, 2020
Peer-review started: March 5, 2020
First decision: March 13, 2020
Revised: May 22, 2020
Accepted: June 23, 2020
Article in press: June 23, 2020
Published online: August 14, 2020
Processing time: 162 Days and 1.3 Hours
Peer-review started: March 5, 2020
First decision: March 13, 2020
Revised: May 22, 2020
Accepted: June 23, 2020
Article in press: June 23, 2020
Published online: August 14, 2020
Processing time: 162 Days and 1.3 Hours
Core Tip
Core tip: Patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) often experience diarrhoea, which may have multiple synchronous causes. Although this has a considerable impact on patient quality of life, differential diagnosis of diarrhoea in patients with GEP-NETs is a relatively unexplored topic, and there is currently no formal clinical guidance. This systematic literature review provides valuable insight on the prevalence of causes of diarrhoea in patients with GEP-NETs, evidence on how these cause are diagnosed in this patient population specifically, the consequences if the true cause(s) of diarrhoea are not ascertained, and suggestions for improving differential diagnosis of GEP-NET diarrhoea.